Research programme: E3 ubiquitin ligase inhibitors - Apeiron Biologics

Drug Profile

Research programme: E3 ubiquitin ligase inhibitors - Apeiron Biologics

Alternative Names: APN-411

Latest Information Update: 14 Jul 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Apeiron Biologics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Ubiquitin-protein ligase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 31 Aug 2016 APN 411 is in preclinical trials for Cancer in Austria (Apeiron Biologics pipeline, August 2016)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Austria (Parenteral)
  • 02 Jan 2013 Apeiron Biologics and Evotec AG agree to collaborate on the development of immunomodulatory therapies for cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top